复方丹参滴丸治疗冠心病心绞痛的Meta分析  

Meta-analysis of CSDP for Coronary Heart Disease Angina

作　　者：肖瑜[1] 刘永军[1] 

机构地区：[1]中国药科大学国际医药商学院,江苏南京211198

出　　处：《中国药物评价》2013年第1期32-36,共5页Chinese Journal of Drug Evaluation

摘　　要：目的:以消心痛治疗作为对照组,评价复方丹参滴丸治疗冠心病心绞痛的临床疗效。方法:检索中国期刊全文数据库(2000～2012年)和万方数据医药信息系统(2000～2012年),按照循证医学的要求,对符合纳入标准的文献采用RevMan5.0专用软件进行Meta分析,选择心绞痛症状疗效、心电图改善效果作为效应指标。结果:对于心绞痛症状疗效的合并OR值为2.54(P<0.00001),95%的CI为[1.89,3.42];心电图改善的合并OR值为2.42(P<0.00001),95%的CI为[1.88,3.12],差异具有统计学意义,治疗组均优于对照组。结论:复方丹参滴丸较消心痛治疗冠心病心绞痛更有效,安全性较高。Objective： To evaluate the clinical efficacy of the CSDP in the treatment of coronary heart disease angina and use isosor- bide dinitrate treatment as a control group. Methods： Retrieve the China Academic Journal （2000 -2012） and Wanfang Data of medical information systems, according to the requirements of evidence-based medicine, Meta-analysis of the literature that met the inclusion crite- ria with the RevManS. 0 software, the effect of angina and the electrocardiogram improvement are selected as the effect indicators. Re- suits： The angina symptoms efficacy of combined OR value of 2. 54 （P 〈 0. 000 01 ）, 95% of CI [ 1.89,3.42 ] ; the ECG improvement combined OR =2.42（P 〈0. 000 01 ）, 95% of CI[ 1.88,3.12], a statistically significant difference in the treatment group than the con- trol group. Conclusion： CDSP treatment of angina pectoris is more effective and higher security than isosorbide dinitrate.

关 键 词：复方丹参滴丸 消心痛 冠心病 心绞痛 META分析 

分 类 号：R259[医药卫生—中西医结合]